Previous Close | 14.29 |
Open | 14.13 |
Bid | 13.00 x 1000 |
Ask | 13.19 x 2200 |
Day's Range | 12.66 - 14.21 |
52 Week Range | 4.34 - 17.50 |
Volume | |
Avg. Volume | 23,635,613 |
Market Cap | 1.071B |
Beta (5Y Monthly) | 0.47 |
PE Ratio (TTM) | 148.67 |
EPS (TTM) | 0.09 |
Earnings Date | Feb 08, 2022 - Feb 14, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Apr 28, 2014 |
1y Target Est | 29.20 |
MIAMI, May 25, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will participate in a fireside chat at the Jefferies Healthcare Conference. The fireside chat will be available through the Conference on June 8, 2022 at 11:00 AM - 11:25 AM Eastern Time. A webcast of the fireside chat will b
MIAMI, May 18, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Joel Batten as Executive Vice President and Head of its U.S. Infectious Disease Franchise effective May 23, 2022. Most recently Mr. Batten has been the Head of the Respiratory Syncytial Virus (RSV) Franchise at Sobi North A
Veru (VERU) stock recently released eye-opening fiscal results and achieved a clinical milestone. The investing community responded with a forceful share-price rally. Investors should let the trend be their friend and stay on the long side of the trade. Source: motorolka / Shutterstock.com Miami-headquartered Veru (NASDAQ:VERU) is a biopharmaceutical company that develops medicines for the management of cancers and infectious diseases like Covid-19. Midday on May 13, VERU stock was shooting up l